Feeds:
Posts
Comments

Search Results for 'Pfizer'

The complication of Pfizer’s Vaccine Distribution’s Plan Reporter : Irina Robu, PhD Even though Pfizer announcing the development of safe and effective vaccine is cause for celebration, scientists and public experts face  the challenge of how to quickly make millions of doses of the vaccine and getting them to hospitals, clinics and pharmacies. But Pfizer […]

Read Full Post »

COVID vaccines by Pfizer, AstraZeneca are probed in Europe after reports of heart inflammation, rare nerve disorder Reporter: Aviva Lev-Ari, PhD, RN PRAC concludes review of signal of facial swelling with COVID-19 vaccine Comirnaty PRAC concludes review of unusual blood clots with low blood platelets1 with Janssen’s COVID-19 vaccine PRAC continues to closely review Comirnaty and COVID-19 Vaccine […]

Read Full Post »

First single-course ‘curative’ CRISPR Shot by Intellia rivals Alnylam, Ionis and Pfizer Reporter: Aviva Lev-Ari, PhD, RN   Intellia to kick-start first single-course ‘curative’ CRISPR shot, as it hopes to beat rivals Alnylam, Ionis and Pfizer by Ben Adams | Oct 19, 2020 10:39am It’s been a good year for Intellia: One of its founders, Jennifer Doudna, […]

Read Full Post »

C.D.C. Reviewing Cases of Heart Problem in Youngsters After Getting Vaccinated and AHA Reassures that Benefits Overwhelm the Risks of Vaccination Reporter: Amandeep Kaur, B.Sc. , M.Sc. The latest article in New York times reported by Apoorva Mandavilli outlines the statement of officials that C.D.C. agency is investigating few cases of young adults and teenagers […]

Read Full Post »

Pfizer buys out Array BioPharma for $11.4 Billion to beef up its oncology offerings Reporter: Stephen J. Williams, PhD As reported in FiercePharma.com: by Angus Liu | Jun 17, 2019 11:42am Three years after purchasing Medivation for $14.3 billion, Pfizer is back with another hefty M&A deal. And once again, it’s betting on oncology. In the first […]

Read Full Post »

Third Boston Pharmaceutical Symposium on May 3, 2019 at Pfizer, Building 2, Kendall Sq., Cambridge MA Reporter: Aviva Lev-Ari, PhD, RN   The Boston Chapter of the American Statistical Association (BCASA) invites you all to attend the Third Boston Pharmaceutical Symposium on May 3, 2019 at Pfizer, Building 2, Kendall Sq., Cambridge MA.   As […]

Read Full Post »

From Thalidomide to Revlimid: Celgene to Bristol Myers to possibly Pfizer; A Curation of Deals, Discovery and the State of Pharma   Curator: Stephen J. Williams, Ph.D. Updated 6/24/2019 Updated 4/12/2019 Updated 2/28/2019 Lenalidomide (brand name Revlimid) is an approved chemotherapeutic used to treat multiple myeloma, mantle cell lymphoma, and certain myedysplastic syndromes.  It is […]

Read Full Post »

Comparing COVID-19 Vaccine Schedule Combinations, or “Com-COV” – First-of-its-Kind Study will explore the Impact of using eight different Combinations of Doses and Dosing Intervals for Different COVID-19 Vaccines Reporter: Aviva Lev-Ari, PhD, RN   The UK’s COVID-19 vaccine rollout commenced in December, and requires an individual to receive two doses of the same vaccine, either […]

Read Full Post »

Top 15 pharmas, then=2026 and now=2020: How the next five years will shake up Big Pharma’s rankings Reporter: Aviva Lev-Ari, PhD, RN   As the pharma industry enters a new decade, the world’s largest drug companies are busy launching new meds, restructuring to focus on innovative offerings and eyeing new technologies. And despite challenges from the COVID-19 pandemic, analysts […]

Read Full Post »

Synopsis for AI & Machine Learning in Clinical Trials, APRIL 12, 2018 PFIZER INNOVATION RESEARCH LAB – CAMBRIDGE, MA   Recap Book http://viewer.zmags.com/publication/9d58c338#/9d58c338/30   Aviva Lev-Ari, PhD, RN, Director and Founder of  LPBI Group,  will attend and cover in Real Time the Conference  @pharma_BI @AVIVA1950 Tweets for AI and Machine Learning in Clinical Trials April 12th, […]

Read Full Post »

Next »

:)